I rated Viatris a "Buy" last October, based on management's completion of "Phase 1" of its business transformation, and initiation of "Phase 2" of their strategic plan — returning to growth.

Viatris has made a play to expand its branded ... Jean-Paul Clozel, presented phase 2 data with platelet aggregation inhibitor selatogrel, saying it has the potential to revolutionise the ...

For fiscal 2024, analysts anticipate Viatris to report an EPS of $2.68, down 8.5% from $2.93 in fiscal 2023. Viatris' shares have declined 5.4% over the past 52 weeks, significantly ...